secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lineage Cell Therapeutics, Inc. (LCTX)
CIK:        0000876343
Form:       8-K
Filed at:   2022-05-12T23:59:59+00:00
Accession:  0001493152-22-013033
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lineage Q1 net loss $7.1M ($0.04/sh); cash $78.1M; pipeline expanded
--------------------------------------------------------------------

- Net loss attributable to Lineage of $7.1M ($0.04/sh) vs $1.4M ($0.01/sh) in Q1 2021.
- Total revenues $5.2M, up from $0.4M YoY, driven by $50M Roche upfront licensing fee.
- Cash and cash equivalents $78.1M as of March 31, 2022.
- Pipeline expanded with two new cell therapy programs: auditory neurons (ANP1) and photoreceptors (PNC1).
- VAC2 Phase 1 NSCLC enrollment completed; IND submission for US testing expected 2H 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/876343/000149315222013033/0001493152-22-013033-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/876343/000149315222013033/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-013033

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer